Finance

Lists
Q3 2026 earnings • released • EPS beat +17.88% • Revenue beat +7.88%
See results
LILY34:BVMF
Eli Lilly And Company BDR
R$246.86
+7.12%
(+16.41) 1D
Oct 29, 3:27:26 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for LILY34...
Open
R$237.93
High
R$251.28
Low
R$237.93
Mkt. cap
1.29T
Avg. vol.
46.08K
Volume
46.37K
52-wk high
R$251.28
52-wk low
R$141.70
Shares outstanding
941.36M
No. of employees
50K
Open
R$237.93
High
R$251.28
Low
R$237.93
Mkt. cap
1.29T
Avg. vol.
46.08K
Volume
46.37K
52-wk high
R$251.28
52-wk low
R$141.70
Shares outstanding
941.36M
No. of employees
50K
News stories
From web sources and news partners
Profile
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 36 countries. Its products are marketed in approximately 90 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named. The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so. The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia
About Eli Lilly And Company BDR
CEODavid A. Ricks
Employees50K
Founded1876
HeadquartersIndianapolis, Indiana, United States
SectorPharmaceutical industry
Websitelilly.com
Last report
Just released
Today, 4:00 PM
Fiscal period
Q3 2026
$7.48 / $6.35
+17.88%beat
Revenue / Est. (USD)
24.40B / 22.62B
+7.88%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
17.60B
19.29B
19.80B
22.97B
Cost of goods sold
3.01B
3.37B
3.58B
3.27B
Cost of revenue
3.01B
3.37B
3.58B
3.27B
Research and development expenses
3.47B
3.80B
3.51B
3.82B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.63B
3.46B
2.93B
3.43B
Operating expense
6.09B
7.26B
6.44B
7.25B
Total operating expenses
9.10B
10.63B
10.02B
10.52B
Operating income
8.50B
8.66B
9.78B
12.46B
Other non operating income
-9.10M
181.20M
170.00M
561.00M
EBT including unusual items
7.23B
8.27B
8.85B
9.25B
EBT excluding unusual items
8.21B
8.89B
9.71B
12.73B
Income tax expense
1.65B
1.63B
1.45B
2.15B
Effective tax rate
22.81%
19.70%
16.43%
23.27%
Other operating expenses
-
-
-
-
Net income
5.58B
6.64B
7.40B
7.10B
Net profit margin
31.72%
34.41%
37.36%
30.88%
Earnings per share
7.02
7.54
8.55
8.38
Interest and investment income
65.00M
672.40M
-
-
Interest expense
-179.60M
-153.30M
-332.00M
-345.00M
Net interest expenses
-114.60M
519.10M
-332.00M
-345.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
8.97B
9.25B
10.29B
12.99B
Gain or loss from assets sale
-
-180.00M
-
-
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps